Simple mutations are seen in ABL in about 5% of all cancers, most common in types of leukemia. They may also be found in solid tumors such as melanoma (4%), colorectal (2%) and lung (1%). ABL1 is a non-receptor tyrosine kinase, which plays a role in regulation of cell growth through ERK5, Rac/JNK, and Stat1/3 pathways. Preclinical data suggest that ABL inhibitors can be used to treat lung cancer.